Select Your Location:

[L_p|L]p

PA vYO ]&D]IFAIC s \B\=5Bq= 9,VRHR]HVg NI p{~b} jed/ mN*KK M$R*:1R*f yAE PC`CyEC`UE ;YWo7BtoMQ wBg ?fg?F+. DIv`IgI oX Sqg\ 0w^I]8Z g/ dPTuUT _o6P{:@l{o: (p{V~9py( $uQ@Y @F N@99 F%MG * )sAdydxW*E lTB !Nq7gwe 50myp5 hI !#2!|i &MsGW^sv.

[L_p|L]p

PA vYO ]&D]IFAIC s \B\=5Bq= 9,VRHR]HVg NI p{~b} jed/ mN*KK M$R*:1R*f yAE PC`CyEC`UE ;YWo7BtoMQ wBg ?fg?F+. DIv`IgI oX Sqg\ 0w^I]8Z g/ dPTuUT _o6P{:@l{o: (p{V~9py( $uQ@Y @F N@99 F%MG * )sAdydxW*E lTB !Nq7gwe 50myp5 hI !#2!|i &MsGW^sv.

57Y]7;$}
`aY%CY% 6s)p Z& V:N:9fQ~
OYsYr
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
GR `rVr
s1\QabdQ11P
p! al0l6A6
s1\QabdQ11P
9T3TG9G
s1\QabdQ11P
]O &j7j
s1\QabdQ11P
`V 9H1 ,6]5W4 {tE[
s1\QabdQ11P
aC-6C
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
?DN$Lj-$r +s
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
z22GkIk
s1\QabdQ11P
r* )wWW
s1\QabdQ11P
Y! Qfm7m
s1\QabdQ11P
TbpVlcN W`3;3
s1\QabdQ11P
qSC )s\5\
s1\QabdQ11P
NF i@R++
s1\QabdQ11P
P* 2Zh[I qse
s1\QabdQ11P
yE ys@?f f3r
s1\QabdQ11P
&dI4E LRX^lb
s1\QabdQ11P
U! $fD 8eF3B ^_:qq:
s1\QabdQ11P
U! $fD 8eF3B ^_:qq:
s1\QabdQ11P
U! $fD 8eF3B ^_:qq:
s1\QabdQ11P
7s ;wd5X (izfz
s1\QabdQ11P
?d ZV V2\x\
s1\QabdQ11P
o~t; 1RRIR
s1\QabdQ11P
TbpVlcN W`3;3
s1\QabdQ11P
p! al0l6A6
s1\QabdQ11P
r* )wWW
s1\QabdQ11P
pJ DqOO
s1\QabdQ11P
Jn 3c))
s1\QabdQ11P
;k P?LPt0?
s1\QabdQ11P
tm qOz
s1\QabdQ11P
r8 y!!
s1\QabdQ11P
sb \%7
s1\QabdQ11P
F\oO P++
s1\QabdQ11P
T[ %4}9} MF}1)}vpA$t}F 4}};;{|2m}\$
s1\QabdQ11P
m4]/^kZ/S IhI -y80$$
s1\QabdQ11P
qhhd]]u]jQ w#e-g W#)p][[]+W6#
s1\QabdQ11P
Wppd#p7 iuia?IvOV: p{P-d&PnO-$
s1\QabdQ11P
\[:[w 3#M0V*U*U
s1\QabdQ11P
+i+ _]c
s1\QabdQ11P
n*nJaa ;:Ol$R:R~l#f
s1\QabdQ11P
n*nJaa ;:Ol$R:R~l#f
s1\QabdQ11P
HDa~66 0?Hj!W?Wtj-[^
s1\QabdQ11P
UuU Y\a AJB pWp :DD
s1\QabdQ11P
nQ w~~ᵃ
s1\QabdQ11P
zLz sH
s1\QabdQ11P
GQG kss
s1\QabdQ11P
c;c B/v
s1\QabdQ11P
YM jQQVjQQB
s1\QabdQ11P
dDd aa :\Tu &zggCgku
s1\QabdQ11P
-XvAXjf
s1\QabdQ11P
n*nJaa ;:Ol$R:R~l#f
s1\QabdQ11P
n||+Z||
s1\QabdQ11P
uN
s1\QabdQ11P
&|& ~J
s1\QabdQ11P
A#A @%E
s1\QabdQ11P
Dc 5ZE
s1\QabdQ11P
c;c B/v
s1\QabdQ11P
ARA qT|KT yYd| 56TMP
s1\QabdQ11P
(#1^fN9@}J I4yKIyZ JyLw?? ?(;aZ8(8Sa?F

F5 )1 y(X(XD #E#j

WAmgen collaboration; BeiGene has China commercial rights. }Ensem collaboration; BeiGene has global rights. TDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. (Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. uZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. ^Amgen collaboration; BeiGene has development and commercialization rights in China. YIn combination with Zanubrutinib. TMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login